Prevail Therapeutics, founded in New York, is a biotechnology company dedicated to developing gene therapies for neurodegenerative disorders, with a particular focus on Parkinson's disease. The company's core mission is to create disease-modifying treatments that can significantly improve the lives of patients suffering from these debilitating conditions. Prevail Therapeutics leverages precision medicine to develop its therapies, aiming to slow or stop the progression of neurodegenerative diseases.

Notable figures associated with Prevail Therapeutics include prominent scientists and industry leaders in biotechnology. The company has attracted significant investment from leading venture capital firms and has made substantial progress in its research and development efforts. Key achievements include advancing multiple gene therapy candidates into clinical trials, demonstrating promising preclinical results, and establishing partnerships with major research institutions. Prevail Therapeutics' work has the potential to make a profound impact on the treatment landscape for neurodegenerative diseases, offering hope to millions of patients worldwide.